Background: Endometrial carcinoma is a of globally perceived problem attributed to genomic molecular defects. Differentiating atypical endometrial hyperplasia from endometrial carcinoma specially in the samples of endometrial curettage is a diagnostic predicament for pathologists. Therefore, the studies of immunoexpression profile for proliferating markers and tumor suppressor genes ascertain the potential malignant precursors. The present study was carried out with theobjectives to study cyclin D1, Ki-67 and p53 for inter variable comparisons in WHO categories of endometrial hyperplasia and type 1, endometrial carcinoma. Methods - IHC was performed using monoclonal antibodies of cyclin D1, Ki-67 and p53 in WHO defined categories of endometrial hyperplasia and type 1 endometrial carcinoma. The results of IHC were statistically analysed and p value less than 0.05 was considered significant. Results - The present study was carried out in Six groups with 15 cases in each group. The immunoexpression of cyclin D1, Ki-67 and p53 were in the increasing grade of hyperplasia and endometrial carcinoma.It is concluded that the IHC of cyclin D1, Ki-67 and p53 can derive conclusive immunostaining that enables the differentiation between atypical endometrial hyperplasia and endometrial carcinoma,type 1,low grade.

Endometrial carcinoma,type 1,endometrial hyperplasia,IHC, Cyclin D1, Ki-67 and p53.